# Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

> **NCT03259425** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 7 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** HF10

## Key facts

- **NCT ID:** NCT03259425
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-03
- **Primary completion:** 2018-09-21
- **Final completion:** 2020-09-25
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** DSMC Recommendation
- **Last updated:** 2022-06-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259425, "Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03259425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*